Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Geoffrey R. Connors MD, FACP Associate Editor

See All Experts

story of the week

Published in Respiratory Medicine

Journal Scan / Research · December 19, 2024

Benralizumab in the Treatment of Patients With Eosinophilic Exacerbations of Asthma and COPD

The Lancet Respiratory Medicine

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Emmett Kistler MD

The Lancet Respiratory Medicine

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial

Lancet Respir Med 2024 Nov 27;[EPub Ahead of Print], S Ramakrishnan, REK Russell, HR Mahmood, K Krassowska, J Melhorn, C Mwasuku, ID Pavord, L Bermejo-Sanchez, I Howell, M Mahdi, S Peterson, T Bengtsson, M Bafadhel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Benralizumab in the Treatment of Patients With Eosinophilic Exacerbations of Asthma and COPD

Additional Info

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial

Further Reading

Benralizumab in the Treatment of Patients With Eosinophilic Exacerbations of Asthma and COPD

Efficacy and Safety of Adjunctive Midodrine Therapy for Vasopressor-Dependent Shock in the ICU

Prevalence of Chronic Airflow Limitation, Emphysema, and Impaired Diffusing Capacity in Relation to Smoking Habits in Middle-Aged Populations

Feasibility of Antibiotic Allergy De-Labeling in the ICU

Impact of Dyspnea on Quality of Life in Adults With Respiratory Symptoms Without a Defined Diagnosis

2024 Top Story in Respiratory Medicine: Dupilumab in COPD

2024 Top Story in Respiratory Medicine: Effect of Metagenomic Sequencing on Clinical Outcomes of Patients With Severe Community-Acquired Pneumonia

Association Between Inability to Stand at ICU Discharge and Readmission

Inability to Perform Sit-to-Stand Among Survivors Admitted to Medical ICUs

Building Teams and Optimizing Practice With Nurse Practitioners and Physician Assistants in the Medical ICU

Effect of a Reduced PCV10 Dose Schedule on Pneumococcal Carriage

Recently Updated